Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
Earnings for Benitec Biopharma Inc. (BNTC)
Earnings in 2024 (TTM): $-22,370,000
According to Benitec Biopharma Inc.'s latest financial reports the company's current earnings (TTM) are $-22,370,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Benitec Biopharma Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2024 | $-22,370,000 | $-21,751,000 |
| 2023 | $-19,562,000 | $-19,562,000 |
| 2022 | $-18,208,000 | $-18,562,000 |
| 2021 | $-13,882,000 | $-13,781,000 |
| 2020 | $-8,274,000 | $-8,301,000 |
| 2019 | $2.87 M | $2.87 M |
| 2018 | $-8,550,650 | $-8,550,650 |
| 2017 | $-4,372,483 | $-4,372,483 |
| 2016 | $-18,503,749 | $-18,503,749 |
| 2015 | $-8,827,410 | $-8,827,410 |
| 2014 | $-10,835,671 | $-10,835,671 |
| 2013 | $-6,838,114 | $-6,423,793 |